Table 3.
Maximum relaxation (E max ) of human bronchi and potency (pD 2 ) observed with chloroquine or phenanthroline in the presence or absence (control) of U73122 (1 μM, an inhibitor of PLCβ), iberiotoxin (0.1 μM, a selective inhibitor of BK Ca channels), thapsigargin (0.1 μM, an inhibitor of the sarcoplasmic reticulum Ca 2+ -ATPase), tetraethylammonium (1 mM, a non-selective potassium channels blocker), H89 (10 μM overnight, a PKA inhibitor), brefeldin A (20 μM overnight, an Epac inhibitor), indomethacin (1 µM, a cyclooxygenases inhibitor) and L-NAME (3 mM, a nitric oxide synthetase inhibitor)
| |
Chloroquine |
Phenanthroline |
|
||
|---|---|---|---|---|---|
| E max (%) | pD 2 | E max (%) | pD 2 | n | |
|
Control |
93 ± 4 |
4.3 ± 0.2 |
96 ± 1 |
4.5 ± 0.1 |
6-10 |
|
U73122 |
96 ± 1 |
4.3 ±0.2 |
96 ± 1 |
4.5 ± 0.1 |
6 |
|
Iberiotoxin |
96 ± 3 |
4.2 ± 0.2 |
97 ± 0.1 |
4.3 ± 0.2 |
6 |
|
Thapsigargin |
99 ± 2 |
4.0 ± 0.1 |
94 ± 2 |
4.0 ± 0.2 |
6 |
|
Tetraethylammonium |
91 ± 3 |
4.2 ± 0.2 |
97 ± 1 |
4.5 ± 0.1 |
5-6 |
|
H89 |
98 ± 1 |
4.6 ± 0.1 |
99 ± 1 |
5.3 ± 0.5 |
5-6 |
|
Brefeldin A |
92 ± 2 |
4.6 ± 0.3 |
97 ± 1 |
4.5 ± 0.1 |
5-6 |
|
Indomethacin |
95 ± 2 |
4.3 ± 0.1 |
97 ± 1 |
4.2 ± 0.2 |
6-7 |
| L-NAME | 94 ± 3 | 4.6 ± 0.2 | 98 ± 1 | 4.4 ± 0.1 | 5 |
Emax values are expressed as a percentage of the relaxation observed with 3 mM theophylline (mean ± SEM of experiments performed on isolated bronchi from 5 to 10 patients).